Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | CALML3 | P27482 | 7/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SDHA | P31040 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827610 | 1.00 | F10 (0.44) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL3826812 | 0.89 | MAOA (0.45) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL5004964 | 0.87 | F10 (0.45) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL14029041 | 0.87 | F10 (0.45) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL5004965 | 0.87 | F10 (0.45) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL3829397 | 0.83 | MAOA (0.56) | F10MAOACALML3MAOBLMNA | |
| SCHEMBL3827590 | 0.83 | MAOA (0.47) | F10MAOACALML3MAOBLMNA | |
| SCHEMBL3829388 | 0.83 | MAOA (0.56) | F10MAOACALML3MAOBLMNA | |
| SCHEMBL3831063 | 0.82 | F10 (0.41) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL3826987 | 0.82 | MAOA (0.60) | F10MAOACALML3MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318431-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| EP-1987025-B1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER PROD INC (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-1987025-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pfizer Products Incorporated (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093904-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER PRODUCTS INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318431-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | HRH2, HRH1, HRH4 | F10 1162/4885MAOA 1117/4885CALML3 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.